Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis

Antimicrob Agents Chemother. 1994 May;38(5):1197-9. doi: 10.1128/AAC.38.5.1197.

Abstract

Concentrations of dapsone, monoacetyldapsone, and pyrimethamine were determined in 36 serum samples from human immunodeficiency virus-infected patients on prophylaxis with once-weekly administration of dapsone-pyrimethamine (200 mg of dapsone-75 mg of pyrimethamine). During day 1 after ingestion, median levels of 1,038 ng of dapsone per ml and 356 ng of pyrimethamine per ml were found. During days 6 to 7, the dapsone level fell to < 20 ng/ml in five of nine serum samples, but the pyrimethamine level remained elevated (125 ng/ml). Concurrent, but separately ingested, didanosine administration did not seem to decrease the drug concentrations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Dapsone / administration & dosage
  • Dapsone / analogs & derivatives
  • Dapsone / blood*
  • Dapsone / therapeutic use*
  • Drug Interactions
  • Female
  • HIV Infections / complications
  • HIV Infections / metabolism*
  • Humans
  • Male
  • Middle Aged
  • Phenotype
  • Pneumonia, Pneumocystis / prevention & control*
  • Pyrimethamine / administration & dosage
  • Pyrimethamine / blood*
  • Pyrimethamine / therapeutic use*
  • Toxoplasmosis, Cerebral / prevention & control*
  • Zidovudine / adverse effects
  • Zidovudine / therapeutic use

Substances

  • Zidovudine
  • Dapsone
  • monoacetyldapsone
  • Pyrimethamine